Invion Ltd (IVX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Invion Ltd (IVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7998
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Invion Ltd (Invion) is a life sciences company that develops products for the treatment of inflammatory diseases such as chronic inflammatory, airway disease and inflammation caused by autoimmune disease. The company’s pipeline products include INV102 nadolol, a beta adrenergic biased ligand targeted to reverse mucous metaplasia in the airway epithelium for the treatment of chronic inflammatory airway diseases; INV103 ala-Cpn10, a naturally occuring human protein for the treatment of chronic inflammation; and INV104 zafirlukast, a leukotriene receptor antagonist for the prevention of asthma attacks. Invion also conducts clinical development programs for developing zafirlukast as a novel non-steroidal, anti-inflammatory treatment to prevent asthma attacks. The company has operations in Melbourne, Australia; and Delaware, the US. Invion is headquartered in Melbourne, Victoria, Australia.

Invion Ltd (IVX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Invion Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Invion Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Invion Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Invion Enters into R&D Agreement with Hudson Institute of Medical 10
Invion Enters into Development and Licensing Agreement with Hovione 11
Invion Enters Into Co-Development Agreement With 3M Drug Delivery Systems For INV102 And INV104 12
Licensing Agreements 13
Chronic Airway Therapeutics to Receive Respiratory Assets from Invion 13
Invion Enters into Licensing Agreement with Cho Group 14
Invion Enters Into Licensing Agreement With Accolade For Zafirlukast 15
Equity Offering 17
Invion Raises USD19.46 Million in Rights Offering of Shares 17
Invion Raises USD0.5 Million in Private Placement of Ordinary Shares 18
Invion Raises USD0.4 Million in Private Placement of Shares 19
Invion to Raise USD15 Million in Private Placement of Shares 20
Invion Completes Rights Offering Of Shares For USD0.8 Million 21
Invion Completes Private Placement Of Shares For US$4.5 Million 23
Invion Completes Private Placement Of Shares For US$1.9 Million 24
Invion Completes Rights Offering Of Shares For US$1 Million 25
Acquisition 27
CBio Completes Acquisition Of Inverseon, Clinical-Stage Pharma Company 27
Invion Ltd – Key Competitors 29
Invion Ltd – Key Employees 30
Invion Ltd – Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Financial Announcements 32
Aug 28, 2018: Invion – Highlights of appendix 4E and full year financial results 32
Corporate Communications 34
Mar 22, 2018: Change to Invion Board of Directors 34
Mar 21, 2018: Leading Ovarian Cancer Expert Dr Andrew Stephens Appointed to Invion’s Advisory Board 35
Dec 01, 2017: Invion Appoints Mr Thian Chew As Director And Chairman 36
Government and Public Interest 37
Jul 05, 2018: Photosoft Efficiently Destroys Ovarian Cancer Cells In Vitro 37
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Invion Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Invion Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Invion Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Invion Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Invion Enters into R&D Agreement with Hudson Institute of Medical 10
Invion Enters into Development and Licensing Agreement with Hovione 11
Invion Enters Into Co-Development Agreement With 3M Drug Delivery Systems For INV102 And INV104 12
Chronic Airway Therapeutics to Receive Respiratory Assets from Invion 13
Invion Enters into Licensing Agreement with Cho Group 14
Invion Enters Into Licensing Agreement With Accolade For Zafirlukast 15
Invion Raises USD19.46 Million in Rights Offering of Shares 17
Invion Raises USD0.5 Million in Private Placement of Ordinary Shares 18
Invion Raises USD0.4 Million in Private Placement of Shares 19
Invion to Raise USD15 Million in Private Placement of Shares 20
Invion Completes Rights Offering Of Shares For USD0.8 Million 21
Invion Completes Private Placement Of Shares For US$4.5 Million 23
Invion Completes Private Placement Of Shares For US$1.9 Million 24
Invion Completes Rights Offering Of Shares For US$1 Million 25
CBio Completes Acquisition Of Inverseon, Clinical-Stage Pharma Company 27
Invion Ltd, Key Competitors 29
Invion Ltd, Key Employees 30

List of Figures
Invion Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Invion Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Invion Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Invion Ltd (IVX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Atos SE:企業の戦略・SWOT・財務情報
    Atos SE - Strategy, SWOT and Corporate Finance Report Summary Atos SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Pegasi Energy Resources Corp:石油・ガス:M&Aディール及び事業提携情報
    Summary Pegasi Energy Resources Corp (PERC) is an energy company that explores, produces, and develops oil and natural gas from its properties. The company produces natural gas and oil through the development of a low geological, repeatable, and high potential project in the Rodessa East Texas oil a …
  • Median Technologies SA (ALMDT):企業の財務・戦略的SWOT分析
    Summary Median Technologies SA (Median) is a medical technology company that develops and markets medical imaging solutions. The company offers clinical trials, imaging services for CT, scientific consulting, image and clinical data management, image data processing and site support, managed service …
  • Swift Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary Swift Biosciences Inc (Swift Biosciences) is a biotechnology company that develops novel research reagents, protocols, and molecular diagnostic tools. The company’s products include 2S hyb DNA library kit, 2S plus DNA library kit, 2S PCR-free DNA library kit, methyl-seq DNA library kit, DNA …
  • Bawag Psk:企業の戦略・SWOT・財務分析
    Bawag Psk - Strategy, SWOT and Corporate Finance Report Summary Bawag Psk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Insulet Corp (PODD)-製薬・医療分野:企業M&A・提携分析
    Summary Insulet Corp (Insulet) is a medical device company that develops, manufactures and distributes OmniPod insulin management system, an insulin infusion system for diabetic patients. OmniPod insulin management system consists of OmniPod, a disposable insulin infusion device and the Personal Dia …
  • Huadian Power International Corporation Ltd (1071):電力:M&Aディール及び事業提携情報
    Summary Huadian Power International Corporation Ltd (HPICL) is an electric utility. It constructs and operates power plants, including coal- or gas-fired generating units and renewable energy projects. The company has plants at the electricity and heat load centers or regions with abundant coal reso …
  • Promore Pharma AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Promore Pharma AB (Promore), formerly Pergamum AB is a biopharmaceutical company that develops peptide-based product candidates for local and topical treatment of infections and wounds. The company’s pipeline products include LL-37 and PXL01 therapeutic peptides. Its PXL01 is used for the pr …
  • Mapletree Investments Pte Ltd:企業の戦略的SWOT分析
    Mapletree Investments Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Westrock Co:企業の戦略・SWOT・財務分析
    Westrock Co - Strategy, SWOT and Corporate Finance Report Summary Westrock Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Hammond Manufacturing Company Ltd (HMM.A):企業の財務・戦略的SWOT分析
    Summary Hammond Manufacturing Company Ltd (Hammond) is a power company that develops, manufactures and distributes electrical and electronic devices. The company offers electrical enclosures, small enclosures, racks and rack cabinets, outlet strips, transformers, and chokes and reactors. Its transfo …
  • Geberit Ag:企業の戦略・SWOT・財務分析
    Geberit Ag - Strategy, SWOT and Corporate Finance Report Summary Geberit Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Adani Enterprises Ltd (ADANIENT)
    Adani Enterprises Ltd (ADANIENT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Dai-ichi Life Holdings, Inc.:企業の戦略・SWOT・財務分析
    Dai-ichi Life Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dai-ichi Life Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • NSD Co Ltd (9759):企業の財務・戦略的SWOT分析
    NSD Co Ltd (9759) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • OJSC IC Allianz :企業の戦略・SWOT・財務情報
    OJSC IC Allianz - Strategy, SWOT and Corporate Finance Report Summary OJSC IC Allianz - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Jones Lang LaSalle Inc (JLL):企業の財務・戦略的SWOT分析
    Jones Lang LaSalle Inc (JLL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Bavarian Nordic AS (BAVA):企業の財務・戦略的SWOT分析
    Bavarian Nordic AS (BAVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Helius Medical Technologies Inc (HSM):製品パイプライン分析
    Summary Helius Medical Technologies Inc (HMT) is a medical device company that offers neurological wellness solutions. The company offers development, licensing and acquisition of non-invasive platform technologies for amplifying the brain’s ability to heal itself. It offers development of technolog …
  • EnergySolutions LLC:企業の戦略的SWOT分析
    EnergySolutions LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆